JAK1 and systemic lupus erythematosus: In particular, baricitinib, a JAK1/2 inhibitor approved for the treatment of RA (73), reduced joint manifestation in non-renal adult SLE patients (n=314) in a phase II randomized controlled trial (RCT) (74).